United Kingdom (UK)
Recombinant monoclonal antibody to MOG. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from phage display M3-24.
UniProt Accession Number of Target Protein: Q63349
Alternative Name(s) of Target: Myelin oligodendrocyte glycoprotein; rMOG
Immunogen: Callithrix jacchus marmosets were used, and experimental allergic encephalomyelitis was induced by the injection of rat MOG (aa1-125) into the marmosettes. The rMOG was expressed in E. coli and purified to homogeneity. The animals were killed 4-70 days after the onset of symptoms of EAE. Bone marrow and spleen cells were obtained from an immunized C. jacchus, the RNA extracted with Trizol reagent and rtPCR used to generate cloning inserts containing Fab portions of IgGk. Phage display was then used to select for the MOG-reactive Fab fragments using the pCOMB3H phage display vector, and binding confirmed using an ELISA.
Specificity: Recognises an epitope which is distinct from M26, M38, M45, M3-8 and M3-31. The epitope recognised is a structural epitope, shown by the lack of recognition of linear MOG peptides. Is unique to recombinant hMOG125 and rMOG125, but is not exposed on recombinant hMOG118; hence this epitope is species-independent, but dependent on the length of the protein (Menge et al, 2011).
Application Notes: This antibody has been proposed for the diagnosis and prognosis of multiple sclerosis (MS) or allergic encephalomyelitis (EAE) by using competition assays to determine if there are autoantibodies present in an individual. It has also been proposed that it could be used to predict the severity of the MS or EAE by detecting the proportion of conformation-specific autoantibodies to linear epitope autoantibodies. This antibody has been used in ELISAs and competition assays to characterise its epitope in relation to other antibodies generated against MOG. It was originally generated and tested as a Fab fragment (vod Budingen et al, 2002). Whilst this has been shown to not bind to hMOG, it has been shown to compete with IgG from MS patients for binding to rMOG (Lalive et al, 2006). Analysis has also been done on the amino acid sequence of this antibody (von Budingen et al, 2006).
Antibody first published in:
von Budingen et al Molecular characterization of antibody specificities against myelin/oligodendrocyte glycoprotein in autoimmune demyelination Proc. Natl. Acad. Sci. U.S.A. 99 (12), 8207-8212 (2002) PMID:12060766
Note on publication:
An analysis of 6 Fab fragments against epitopes on MOG, identifying at least 4 separate epitopes. Analysis of these epitopes including competition assays with marmoset auto-antibodies, human auto-antibodies from MS patients, and confirmation that the epit